Q-omics provides the consensus-scored MIR6775 profile across patient tissues and cancer cell-line models. MIR6775 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR6775 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, MIR6775 RNA expression shows 10,820 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where MIR6775 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6775 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6775 survival associations across molecular data types. MIR6775 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6775 RNA expression–survival associations across cancer types. High MIR6775 expression shows unfavorable associations in KIRC, THYM, COAD, KIRP and OV, but favorable associations in UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR6775 RNA expression.
This table summarizes MIR6775 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6775. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6775 shows lower tumor expression in STAD and THCA and higher tumor expression in COAD, KIRC, LUAD and KIRP. The COAD box plot shows higher MIR6775 RNA expression in tumor versus normal tissue (log2 FC = +0.413, t-test p = .005).
This table shows molecular features associated with MIR6775 in patient tissues and cancer cell lines. In patient samples, MIR6775 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
